Localized hypermutation is the major driver of meningococcal genetic variability during persistent asymptomatic carriage ‌ Green, LR, Al-Rubaiawi, AA, Al-Maeni, MARM, Harrison, OB, Blades, M, Oldfield, NJ, Turner, DPJ, Maiden, MCJ, Bayliss, CD

Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019–2021 ‌ Ratcliffe, H, Tiley, KS, Andrews, N, Amirthalingam, G, Vichos, I, Morey, E, Douglas, NL, Marinou, S, Plested, E, Aley, P, Galiza, EP, Faust, SN, Hughes, S, Murray, CS, Roderick, M, Shackley, F, Oddie, SJ, Lees, T, Turner, DPJ, Raman, M, Owens, S, Turner, P, Cockerill, H, Lopez Bernal, J, Linley, E, Borrow, R, Brown, K, Ramsay, ME, Voysey, M, Snape, MD

Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme ‌ Carr, JP, MacLennan, JM, Plested, E, Bratcher, HB, Harrison, OB, Aley, PK, Bray, JE, Camara, S, Rodrigues, CMC, Davis, K, Bartolf, A, Baxter, D, Cameron, JC, Cunningham, R, Faust, SN, Fidler, K, Gowda, R, Heath, PT, Hughes, S, Khajuria, S, Orr, D, Raman, M, Smith, A, Turner, DPJ, Whittaker, E, Williams, CJ, Zipitis, CS, Pollard, AJ, Oliver, J, Morales-Aza, B, Lekshmi, A, Clark, SA, Borrow, R, Christensen, H, Trotter, C, Finn, A, Maiden, MC, Snape, MD

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-i... ‌ Liu, X, Shaw, RH, Stuart, ASV, Greenland, M, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Dinesh, T, England, A, Faust, SN, Ferreira, DM, Finn, A, Green, CA, Hallis, B, Heath, PT, Hill, H, Lambe, T, Lazarus, R, Libri, V, Long, F, Mujadidi, YF, Plested, EL, Provstgaard-Morys, S, Ramasamy, MN, Ramsay, M, Read, RC, Robinson, H, Singh, N, Turner, DPJ, Turner, PJ, Walker, LL, White, R, Nguyen-Van-Tam, JS, Snape, MD

Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents ‌ Ratcliffe, H, Tiley, K, Longet, S, Tonry, C, Roarty, C, Watson, C, Amirthalingam, G, Vichos, I, Morey, E, Douglas, NL, Marinou, S, Plested, E, Aley, PK, Galiza, E, Faust, SN, Hughes, S, Murray, C, Roderick, MR, Shackley, F, Oddie, S, Lee, TWR, Turner, DPJ, Raman, M, Owens, S, Turner, PJ, Cockerill, H, Lopez Bernal, J, Ijaz, S, Poh, J, Shute, J, Linley, E, Borrow, R, Hoschler, K, Brown, KE, Carroll, MW, Klenerman, P, Dunachie, SJ, Ramsay, M, Voysey, M, Waterfield, T, Snape, MD

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV,... ‌ Shaw, RH, Liu, X, Stuart, ASV, Greenland, M, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Dejnirattisai, W, Dinesh, T, Faust, SN, Ferreira, DM, Finn, A, Green, CA, Hallis, B, Heath, PT, Hill, H, Lambe, T, Lazarus, R, Libri, V, Long, F, Mujadidi, YF, Plested, EL, Morey, ER, Provstgaard-Morys, S, Ramasamy, MN, Ramsay, M, Read, RC, Robinson, H, Screaton, GR, Singh, N, Turner, DPJ, Turner, PJ, Vichos, I, Walker, LL, White, R, Nguyen-Van-Tam, JS, Snape, MD

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a sing... ‌ Stuart, ASV, Shaw, RH, Liu, X, Greenland, M, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Darton, T, Dinesh, T, Duncan, CJA, England, A, Faust, SN, Ferreira, DM, Finn, A, Goodman, AL, Green, CA, Hallis, B, Heath, PT, Hill, H, Horsington, BM, Lambe, T, Lazarus, R, Libri, V, Lillie, PJ, Mujadidi, YF, Payne, R, Plested, EL, Provstgaard-Morys, S, Ramasamy, MN, Ramsay, M, Read, RC, Robinson, H, Screaton, GR, Singh, N, Turner, DPJ, Turner, PJ, Vichos, I, White, R, Nguyen-Van-Tam, JS, Snape, MD